Posts

Eli Lilly to Acquire Merida Biosciences for Up to $2.875 Billion

on

FDA approves first-in-class Mimrylo for rare blood cancer

on

Electra Therapeutics files for Nasdaq IPO to fund Phase 2/3 immunology program

on

Orexin drugs spark a new multibillion-dollar race to control wakefulness

on

Upcoming and On-Demand Webinars

on

BioNTech–Genentech Halt Personalized Cancer Vaccine Trial After Survival Imbalance

on

China’s biotech rise is becoming a U.S. national-security concern

on

CRISPR Therapeutics advances highest-dose CTX310 study after durable cholesterol reductions

on

Novartis keeps its IL-6 bet alive after Novo Nordisk trial failure

on

Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50 Million

on

Teva Offers Up to $125 Million for BioXcel’s Neuroscience Assets

on

AusperBio raises $120 million to advance hepatitis B therapy toward Phase 3 and commercialization

on

Lilly’s Foundayo Oral GLP-1 Prescriptions Cross 40,000

on

FDA approves Gilead’s Bixlenvo once-daily HIV combination tablet

on

Generate:Biomedicines releases early GB-0895 respiratory data after ERS poster leak

on

Chiesi Highlights Rare-Disease Research and Community Support at SSIEM 2026

on

Gates commits up to $35 million to ProFound’s preeclampsia research

on

Friday Five: Abbott and Roche win FDA decisions as AI-device evidence gap draws scrutiny

on

Metriport raises $26M to make fragmented patient records searchable at the point of care

on

BMS Adds $173 Million to Radiopharmaceutical Manufacturing Expansion

on

Artis BioSolutions expands genetic-medicine manufacturing with Bilbao center

on

Osivax licenses GC Biopharma’s flu vaccine to pursue a single-shot combination vaccine

on

Fifth Circuit Rejects PhRMA Challenge to Medicare Drug-Price Negotiation

on

Engineered tRNA offers a potential new route for treating genetic disease

on

Tezspire scores Phase 3 win in eosinophilic esophagitis, challenging Dupixent

on

Vitruvias shuts down after thyroid-drug recall as Baxter expands injectable recalls

on

Brepocitinib Shows Sustained Skin Benefits in Phase 3 Dermatomyositis Trial

on